Your browser doesn't support javascript.
loading
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
Abraham, Jean E; Hiller, Louise; Dorling, Leila; Vallier, Anne-Laure; Dunn, Janet; Bowden, Sarah; Ingle, Susan; Jones, Linda; Hardy, Richard; Twelves, Christopher; Poole, Christopher J; Pharoah, Paul D P; Caldas, Carlos; Earl, Helena M.
Afiliação
  • Abraham JE; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. ja344@medschl.cam.ac.uk.
  • Hiller L; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. ja344@medschl.cam.ac.uk.
  • Dorling L; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. ja344@medschl.cam.ac.uk.
  • Vallier AL; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. ja344@medschl.cam.ac.uk.
  • Dunn J; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. l.hiller@warwick.ac.uk.
  • Bowden S; Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. ld429@medschl.cam.ac.uk.
  • Ingle S; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. anne-laure.vallier@addenbrookes.nhs.uk.
  • Jones L; Cambridge Breast Unit and Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK. anne-laure.vallier@addenbrookes.nhs.uk.
  • Hardy R; Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. j.a.dunn@warwick.ac.uk.
  • Twelves C; Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. s.j.bowden@bham.ac.uk.
  • Poole CJ; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. susan.ingle@addenbrookes.nhs.uk.
  • Pharoah PD; NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Box 277, Hills Road, Cambridge, CB2 0QQ, UK. susan.ingle@addenbrookes.nhs.uk.
  • Caldas C; Department of Oncology, Cambridge Cancer Trials Centre, Box 279 (S4), Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. susan.ingle@addenbrookes.nhs.uk.
  • Earl HM; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Box 193, Cambridge, CB2 0QQ, UK. linda.jones@addenbrookes.nhs.uk.
BMC Med ; 13: 306, 2015 Dec 29.
Article em En | MEDLINE | ID: mdl-26715442
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Quimioterapia Adjuvante / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Quimioterapia Adjuvante / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article